# PT-141 References: The Sources Behind the Datasheet

> PT-141 references — every source behind the datasheet. Peer-reviewed studies and the FDA label for PT-141 (bremelanotide), with PMIDs, DOIs, and PubMed links.

Every claim on this datasheet maps to a numbered source below — peer-reviewed studies, reviews, and the FDA prescribing information.

## How to read this list

These are the PT-141 references behind every numbered claim on this site. Each entry carries its authors, journal, year, and a PubMed link or DOI so a careful reader can verify the source directly. The list is ordered to match the inline citation numbers used across the datasheet. Where a finding is contested — such as the 2008 erectile-dysfunction study now under a 2023 Expression of Concern — that status is flagged on the page that cites it, not buried here.

## References

[1] Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. https://pubmed.ncbi.nlm.nih.gov/12851303/
[2] Pfaus J, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101:10201-10204. https://pubmed.ncbi.nlm.nih.gov/15226502/
[3] Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
[4] Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. https://pubmed.ncbi.nlm.nih.gov/31599847/
[5] Thurston L, Hunjan T, Mills EG, Wall MB, Ertl N, Phylactou M, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Clin Invest. 2022;132(19):e152341. https://pubmed.ncbi.nlm.nih.gov/36189794/
[6] Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. 2025;267:110299. https://pubmed.ncbi.nlm.nih.gov/39793696/
[7] U.S. Food and Drug Administration / DailyMed. Bremelanotide Injection — US Prescribing Information. 2019. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9
[8] Nappi RE, Tiranini L, Martini E, Bosoni D, Righi A, Cucinella L. Medical Treatment of Female Sexual Dysfunction. Urol Clin North Am. 2022. https://pubmed.ncbi.nlm.nih.gov/35428435/
[9] Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel). 2020;13(3):40. https://pubmed.ncbi.nlm.nih.gov/32151051/
[10] Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79:1599-1606. https://pubmed.ncbi.nlm.nih.gov/31312037/
[11] Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020;54(7):684-690. https://pubmed.ncbi.nlm.nih.gov/31893927/
[12] Cipriani S, Maseroli E, Vignozzi L. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert Opin Pharmacother. 2023;24(1):15-21. https://pubmed.ncbi.nlm.nih.gov/36242769/
[13] Hellstrom WJ. Clinical applications of centrally acting agents in male sexual dysfunction. Int J Impot Res. 2008. https://pubmed.ncbi.nlm.nih.gov/18552830/
[14] Pyke RE, Clayton AH. Effect Size in Efficacy Trials of Women With Decreased Sexual Desire. Sex Med Rev. 2018. https://pubmed.ncbi.nlm.nih.gov/29576442/
[15] Shadiack AM, Althof S. Preclinical effects of melanocortins in male sexual dysfunction. Int J Impot Res. 2008. https://pubmed.ncbi.nlm.nih.gov/18552829/

---

A carbon-spec datasheet of the PT-141 record — the one FDA-approved indication, the off-label boundary, and the unregulated research-chemical form each logged to source and read like a manufacturer's spec, with no clinic behind the sheet and nothing here dosed, priced, or sold.